Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sex differences have been described in diabetes cardiovascular outcome trials (CVOTs). PURPOSE: We systematically reviewed for baseline sex differences in cardiovascular (CV) risk factors and CV protection therapy in diabetes CVOTs. DATA SOURCES: Randomized placebo-controlled trials examining the effect of diabetes medications on major adverse cardiovascular events in people ≥18 years of age with type 2 diabetes. STUDY SELECTION: Included trials reported baseline sex-specific CV risks and use of CV protection therapy. DATA EXTRACTION: Two reviewers independently abstracted study data. DATA SYNTHESIS: We included five CVOTs with 46,606 participants. We summarized sex-specific data using mean differences (MDs) and relative risks (RRs) and pooled estimates using random effects meta-analysis. There were fewer women than men in included trials (28.5–35.8% women). Women more often had stroke (RR 1.28; 95% CI 1.09, 1.50), heart failure (RR 1.30; 95% CI 1.21,1.40), and chronic kidney disease (RR 1.33; 95% CI 1.17; 1.51). They less often used statins (RR 0.90; 95% CI 0.86, 0.93), aspirin (RR 0.82; 95% CI 0.71, 0.95), and β-blockers (RR 0.93; 95% CI 0.88, 0.97) and had a higher systolic blood pressure (MD 1.66 mmHg; 95% CI 0.90, 2.41), LDL cholesterol (MD 0.34 mmol/L; 95% CI 0.29, 0.39), and hemoglobin A1c (MD 0.11%; 95% CI 0.09, 0.14 [1.2 mmol/mol; 1.0, 1.5]) than men. LIMITATIONS: We could not carry out subgroup analyses due to the small number of studies. Our study is not generalizable to low CV risk groups nor to patients in routine care. CONCLUSIONS: There were baseline sex disparities in diabetes CVOTs. We suggest efforts to recruit women into trials and promote CV management across the sexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Despite this, women have been underrepresented in recent CVOTs in diabetes, comprising between 28.5 and 35.8% of participants (287).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 3×
“Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (18,26,27).”
BackgroundThe progression from hypertension to congestive heart failure
Levy, D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530440037034 · Cited by 2,155 · cited 1×
“body composition, hormone or reproductive factors, endothelial inflammation, and microvascular function (40) or to the presence of diabetes and hypertension (potent risk factors forheart failure inwomen) (41).”
BackgroundSmith, S. C., Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L., Jones, D., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,104
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173 · cited 1×
“participants had established type 2 diabetes and CVD or risk factors for CVD (indication for statin) (31).”
BackgroundSex and gender disparities in the epidemiology and outcomes of chronic kidney disease
Carrero, J. J., Hecking, M., Chesnaye, N. C., & Jager, K. J. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.181 · Cited by 923 · cited 1×
“Ahigher prevalence of CKD inwomenhas also been described, which might in part be due to the longer life expectancy of women or overdiagnosis with estimating equations (42).”
BackgroundPeters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805
Self-citationSex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 757
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3260-6 · Cited by 701
Self-citationEzekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676 · cited 2×
“had heart failure more often than men (indication forb-blockers) (35), alongwith stroke (indication for aspirin and statin) and CKD (indication for statin) (32).”
BackgroundEvidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 579
Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention
Melloni, C., Berger, J. S., Wang, T. Y., Gunes, F., Stebbins, A., Pieper, K. S., Dolor, R. J., Douglas, P. S., Mark, D. B., & Newby, L. K. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.868307 · Cited by 455
Peters, S. A. E., Muntner, P., & Woodward, M. (2019) · Circulation · doi:10.1161/circulationaha.118.035550 · Cited by 434
Self-citationDeterminants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388
Huxley, R. R., Peters, S. A. E., Mishra, G. D., & Woodward, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70248-7 · Cited by 383
Self-citationSex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
Wexler, D. J., Grant, R. W., Meigs, J. B., Nathan, D. M., & Cagliero, E. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.514 · Cited by 339
Ohkuma, T., Komorita, Y., Peters, S. A. E., & Woodward, M. (2019) · Diabetologia · doi:10.1007/s00125-019-4926-x · Cited by 279
Self-citationFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
Jochmann, N., Stangl, K., Garbe, E., Baumann, G., & Stangl, V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi397 · Cited by 272
Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies
Sφrensen, H. T., Lash, T. L., & Rothman, K. J. (2006) · Hepatology · doi:10.1002/hep.21404 · Cited by 236
Stroke in Women: Disparities and Outcomes
Persky, R. W., Turtzo, L. C., & McCullough, L. D. (2010) · Current Cardiology Reports · doi:10.1007/s11886-009-0080-2 · Cited by 224
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13028 · Cited by 183
Peters, S. A. E., Huxley, R. R., Sattar, N., & Woodward, M. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0462-5 · Cited by 176 · cited 1×
“While sex differences in diabetesmight be due to biological factors, body composition, fat distribution, or sex hormones (2), variances might also be related to disparities in cardiovascular (CV) risk factor management (e.”
BackgroundSelf-citationSex differences in the burden and complications of diabetes
Peters, S. A. E., & Woodward, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1005-5 · Cited by 172
Self-citationFerrara, A., Mangione, C. M., Kim, C., Marrero, D. G., Curb, D., Stevens, M., Selby, J. V., & for the Translating Research Into Action for Diabetes (TRIAD) Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1244 · Cited by 165
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153
Sex differences in risk factor management of coronary heart disease across three regions
Zhao, M., Vaartjes, I., Graham, I., Grobbee, D., Spiering, W., Klipstein-Grobusch, K., Woodward, M., & Peters, S. A. (2017) · Heart · doi:10.1136/heartjnl-2017-311429 · Cited by 144
Self-citationSex and gender differences in therapy of type 2 diabetes
Kautzky‐Willer, A., & Harreiter, J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.07.012 · Cited by 117
Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
Rådholm, K., Zhou, Z., Clemens, K., Neal, B., & Woodward, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13876 · Cited by 82 · cited 1×
“CVOTs, the participation of women was low, aswe havedescribedpreviously (30).”
BackgroundSelf-citationon behalf of the EMPA-REG OUTCOME® investigators, Zinman, B., Inzucchi, S. E., Wanner, C., Hehnke, U., George, J. T., Johansen, O. E., & FITCHETT, D. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4630-2 · Cited by 71
Self-citationCarcel, C., Woodward, M., Balicki, G., Koroneos, G. L., de Sousa, D. A., Cordonnier, C., Lukaszyk, C., Thompson, K., Wang, X., Davies, L., et al. (2019) · International Journal of Stroke · doi:10.1177/1747493019851292 · Cited by 64 · cited 2×
“finding that has also been described in systematic reviews of CV prevention and stroke (28,29).”
BackgroundSelf-citationAlfredsson, J., Green, J. B., Stevens, S. R., Reed, S. D., Armstrong, P. W., Angelyn Bethel, M., Engel, S. S., McGuire, D. K., Van de Werf, F., Hramiak, I., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13377 · Cited by 59
Sex disparities in the management of coronary heart disease in general practices in Australia
Lee, C. M. Y., Mnatzaganian, G., Woodward, M., Chow, C. K., Sitas, F., Robinson, S., & Huxley, R. R. (2019) · Heart · doi:10.1136/heartjnl-2019-315134 · Cited by 59 · cited 1×
“As sex disparities in the use of RAAS blockade have been described in patients with diabetes in routine care previously (11), this finding might be suggestive of recent change.”
BackgroundSelf-citationWilliams, J. L. S., Lynch, C. P., Winchester, R. J., Thomas, L., Keith, B. A., & Egede, L. E. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0329 · Cited by 49
Diabetes and the Female Disadvantage
Woodward, M., Peters, S. A., & Huxley, R. R. (2015) · Women's Health · doi:10.2217/whe.15.67 · Cited by 48
Self-citationBethel, M. A., Green, J. B., Milton, J., Tajar, A., Engel, S. S., Califf, R. M., Holman, R. R., & on behalf of the TECOS Executive Committee (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12441 · Cited by 46
Who refuses enrollment in cardiac clinical trials?
Biswas, M. S., Newby, L. K., Bastian, L. A., Peterson, E. D., & Sugarman, J. (2007) · Clinical Trials · doi:10.1177/1740774507079434 · Cited by 35
Šekerija, M., Poljicanin, T., Erjavec, K., Liberati-Cizmek, A.-M., Prašek, M., & Metelko, Z. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6094 · Cited by 24
Knudsen, J. S., Thomsen, R. W., Pottegård, A., Knop, F. K., & Sørensen, H. T. (2018) · Diabetes Care · doi:10.2337/dc18-0999 · Cited by 21
Clinical trial enrolment favours men
Norberg, H. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz146 · Cited by 20 · cited 1×
“reviewsof CVprevention (28), stroke (29), and heart failure (38).”
BackgroundMiller, R. G., & Costacou, T. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1240-4 · Cited by 15
Research works printed but not linked: 1
- Diabetes Canada . Cardiovascular protection in people with diabetes. Accessed 27 December 2019. Available from https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-23#panel-tab_Recommendations
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“This analysis also described differing patterns of cardiovascular complications in women compared with men, and poorer management of cardiovascular risk factors in women [287].”
Sex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
“Therefore, regardless of their comorbidities, fewer women with type 2 diabetes were treated in accordance with the guidelines than men [70].”
BackgroundGender-Related Factors in Medication Adherence for Metabolic and Cardiovascular Health
Venditti, V., Bleve, E., Morano, S., & Filardi, T. (2023) · Metabolites · doi:10.3390/metabo13101087 · Cited by 134
“However, current studies about treatment outcomes between men and women still lack good female representation and are therefore unreliable [30,31].”
BackgroundAge and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 61
“3,18 We aimed to perform a systematic review and meta-analysis of both aggregate and individual participant trial data to estimate whether the efficacy of SGL2i, GLP1ra and DPP4i therapy for type 2 diabetes differs by age and sex.”
Metadata
- Authors
- Clemens, K. K., Woodward, M., Neal, B., & Zinman, B.
- Affiliations
- Western University (CA)
- Johns Hopkins University (US)
- The George Institute for Global Health (AU)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-04-13
- Volume
- 43
- Issue
- 5
- Pages
- 1157-1163
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3016435336
- Cited by
- 70
- References
- 52
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 12 · 2023: 13 · 2022: 11 · 2021: 11 · 2020: 2
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Sex and Gender in Healthcare
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Social Sciences › Gender Studies › Diversity and Career in Medicine
- Keywords
- sex disparities, type 2 diabetes, cardiovascular outcome trials, major adverse cardiovascular events, cardiovascular risk factors, statins, aspirin, beta-blockers, stroke, heart failure, chronic kidney disease, HbA1c, LDL cholesterol, systolic blood pressure, women in clinical trials, sex differences in drug response
- MeSH terms
- Adolescent, Adrenergic beta-Antagonists, Adult, Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Diabetic Angiopathies, Female, Heart Failure, Glycated Hemoglobin, Humans, Male, Middle Aged, Sex Characteristics, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Renal Insufficiency, Chronic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.